SynthesisMedicine2017
Ki67 is a biological marker of malignant risk of gastrointestinal stromal tumors: A systematic review and meta-analysis.
Synthesis in Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- The prognostic role of Ki-67/MIB-1 in meningioma: A systematic review with meta-analysis.Medicine · 2020Pooled it
- Pretreatment Tumor DNA Sequencing of KIT and PDGFRA in Endosonography-Guided Biopsies Optimizes the Preoperative Management of Gastrointestinal Stromal Tumors.Molecular diagnosis & therapy · 2020Trial
- Intestinal tumors in neurofibromatosis 1 with special reference to fatal gastrointestinal stromal tumors (GIST).Molecular genetics & genomic medicine · 2019Trial
- Diagnostic value and clinical significance of Ki-67, PI3K, and Fascin in patients with oral squamous cell carcinoma.Journal of medical biochemistry · 2025Article
- Association of recurrence with patient and tumor factors in gastrointestinal stromal tumors of small intestine: A single-institutional retrospective study.Oncology letters · 2025Article
- Cell-to-cell adhesion via CD54 (intercellular adhesion molecule-1)-associated cell proliferation in diffuse large B-cell lymphoma cases.Journal of clinical and experimental hematopathology : JCEH · 2024Article
- Gastrointestinal Stromal Tumors: A Retrospective Study at a Tertiary Care Center in Saudi Arabia in the Last Decade.Cureus · 2024Article
- Nomogram for the preoperative prediction of Ki-67 expression and prognosis in stage IA lung adenocarcinoma based on clinical and multi-slice spiral computed tomography features.BMC medical imaging · 2024Article
- Microvessel density in patients with gastrointestinal stromal tumors: A systematic review and meta-analysis.World journal of methodology · 2023Article
- Prognostic analysis of 2-5 cm diameter gastric stromal tumors with exogenous or endogenous growth.World journal of surgical oncology · 2023Review
- Contrast enhanced magnetic resonance imaging-based radiomics nomogram for preoperatively predicting expression status of Ki-67 in meningioma: a two-center study.Quantitative imaging in medicine and surgery · 2023Article
- Clinical characteristics and outcomes of gastrointestinal stromal tumor patients receiving surgery with or without TKI therapy: a retrospective real-world study.World journal of surgical oncology · 2023Article
- Building contrast-enhanced CT-based models for preoperatively predicting malignant potential and Ki67 expression of small intestine gastrointestinal stromal tumors (GISTs).Abdominal radiology (New York) · 2022Article
- Associations of CD34, Ki67, layer of invasion and clinical pathological characteristics, prognosis outcomes in gastrointestinal stromal tumors-a retrospective cohort study.Translational cancer research · 2022Article
- Ki67 for evaluating the prognosis of gastrointestinal stromal tumors: A systematic review and meta-analysis.Oncology letters · 2022Article
- Gastric and Small Intestine Gist: Results of 156 Cases in 20 Years.Journal of gastrointestinal cancer · 2022Article
- Endoscopic Ultrasonography-guided Fine-needle Aspiration Cytology Combined with a Cell-block Method for Gastrointestinal Subepithelial Lesions.Internal medicine (Tokyo, Japan) · 2022Article
- A Panel of Tumor Biomarkers to Predict Complete Pathological Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer.Oncology research · 2022Article
- Long non-coding RNA LINC00511 promotes proliferation, invasion, and migration of non-small cell lung cancer cells by targeting miR-625-5p/GSPT1.Translational cancer research · 2021Article
- Onodera's Prognostic Nutritional Index is a novel and useful prognostic marker for gastrointestinal stromal tumors.World journal of gastrointestinal surgery · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKi67 is a good marker of cell proliferation in a variety of tumors. High ki67 levels are usually associated with poor prognosis. However, the relationship between Ki67 expression and the risk of malignancy of gastrointestinal stromal tumors (GISTs) is still poorly defined. The current meta-analysis was initiated to address this issue.
methodsStudies reporting Ki67 expression and the risk of malignancy in GIST were found by searching Cochrane Library, PubMed, Medline, and Embase until October 31, 2016. A total of 9 studies involving 982 patients were included. Pooled odds ratio (OR) estimates and 95% confidence intervals (CIs) were calculated using a fixed-effect model.
resultsMeta-analysis showed no significant difference in the incidence of Ki67 overexpression between the very low NIH group and the low NIH group (OR: 0.66, 95% CI: 0.25-1.76; P = .41, Pheterogeneity = .25). However, the incidence of Ki67 overexpression gradually increased from the low NIH group to the high NIH group (OR: 0.46, 95% CI: 0.27-0.80; P = .005, Pheterogeneity = .13) and (OR: 0.22, 95% CI: 0.15-0.34; P < .00001, Pheterogeneity = .33).
conclusionsThere were more GIST patients with Ki67 overexpression in the intermediate and high NIH groups than in the low NIH group. Ki67 overexpression may be a useful marker of the risk of malignant GIST transformation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.